Cantel Medical's Mar Cor Purification Subsidiary Acquires G.E.M. Water Systems ... Establishing a Nationwide Reach in Water Treatment

LITTLE FALLS, N.J., Aug. 3 /PRNewswire-FirstCall/ -- CANTEL MEDICAL CORP. (NYSE: CMN ), through its Mar Cor Purification subsidiary, has continued the expansion of its water purification and filtration segment by purchasing the assets of Los Angeles-based G.E.M. Water Systems Int'l, ...

Orexigen(R) Therapeutics Announces Second Quarter 2009 Financial Results

...ated costs. "The recent completion of the cor Phase 3 program was a major milestone for Orexigen... co-primary endpoints. Key top-line data from the cor Phase 3 program include the following: ...t;0.001). Key secondary endpoints met in the cor Phase 3 program included significant improvements ...

-Contrave(R) Obesity Research Phase 3 Program Meets Co-Primary and Key Secondary Endpoints; Exceeds FDA Efficacy Benchmark for Obesity Treatments-

... half of 2010. Key top-line data from the cor Phase 3 program include the following: 4... Key secondary endpoints met across the entire cor Phase 3 program included significant improvements ...as generally well tolerated by patients across the cor Phase 3 program. The...

NUCYNTA(TM) (tapentadol) CII Immediate Release Tablets Now Available for Relief of Moderate to Severe Acute Pain

...atients with conditions accompanied by hypoxia, hypercapnia or decreased respiratory reserve such as: asthma, chronic obstructive pulmonary disease or cor pulmonale, severe obesity, sleep apnea syndrome, myxedema, kyphoscoliosis, CNS depression, or coma. In such patients, even usual therapeutic doses of...

Xanodyne Announces Appointment of Mr. Vaughn M. Kailian of MPM Capital to the Board of Directors

... and the New England Healthcare Institute. Mr. Kailian has numerous accomplishments in the pharmaceutical industry including serving as CEO of cor Therapeutics, Inc. (1990-2002) where he took the company public in 1991, raised almost $1 billion in public market capital, and led the $2 billion mer...

Rcadia Medical Imaging Closes $3.3 Million Investment Led by BioVentures Investors

... -- Rcadia Medical Imaging, Ltd., developer of the cor Analyzer(TM) software for the automated analysis o...ients. Immediately after a Coronary CTA study, the cor Analayzer(TM) identifies patients who need further...ancing will fund the full commercial launch of the cor Analyzer(TM) and the establishment of a U.S. offic...

Conrad A. Conrad Elected Chairman of the Board for Rural/Metro Corporation

...ad joined the Rural/Metro Board of Directors in October 2005 and has served as a member of both the Audit and Compensation committees. He succeeds Mr. cor Clement, who announced earlier this year he would retire from the Board of Directors at the end of June. "I am honored to serve as Chairman of the B...

Landmark Study Aims to Improve Osteoporosis Care Standards Worldwide

...se as the population ages. About the Center for Outcomes Research (COR) cor is based at the University of Massachusetts, Worcester, MA, USA. The mission of cor is to collect and evaluate data that reflect real world practices and outco...

Memory Pharmaceuticals Appoints Vaughn M. Kailian Interim President & Chief Executive Officer

..., Mr. Kailian was the Chief Executive Officer, President, and a director of cor Therapeutics, Inc. He became the CEO of cor shortly after the company was founded, took the company public in 1991, rai...

More>>

COR in Biological Technology

Follica Appoints Drug Development and Dermatology Veteran, William D. Ju, as Chief Executive Officer

... technology. The firm's investments in life sciences include: ArthroCare, Aspreva Pharmaceuticals Corporation (acquired by Galenica group, SWX: GALN), cor Therapeutics (acquired by Millennium Pharmaceuticals), Corixa (acquired by GlaxoSmithKline, GSK), Coulter Pharmaceutical (acquired by Corixa Pharmaceu...

Physicians in Europe Rate Novartis #1 on Service Delivery, While Merck Earns Top Honors in the US

...sician/rep relationships for each measured company, using TNS Healthcare's proprietary TRI*M(TM) Index. R ela t ionship S cor e s Fall e ven f or T o p C o mpanies Even for companies earning high ratings amon...

Delcath Adds Senior Pharmaceutical Professional to Its Board of Directors

...ed the appointment of Roger G. Stoll, Ph.D. to Delcath's Board of Directors. Dr. Stoll is Executive Chairman of Cortex Pharmaceuticals, Inc. (Amex: cor ), a biotechnology company specializing in the treatment of central nervous system disorders. (Logo: http://www.newscom.com/cgi-bin/prnh/...

Global Study Shows That Majority of Women with Osteoporosis Do Not Consider Themselves at Higher Risk for Fractures

...://www.outcomes.org/glow/ About the Center for Outcomes Research (COR) cor is based at the University of Massachusetts, Worcester, MA, USA. The mission of cor is to collect and evaluate data that reflect real world practices and outco...

MAP Pharmaceuticals Appoints Marco Rosa Vice President of Human Resources

...commercial launch of several ophthalmology and surgical microscopy devices. Prior to Carl Zeiss, Mr. Rosa served as Vice President, Human Resources at cor Therapeutics, Inc., building the development and commercial organizations and launching Integrilin(R) in the cardiovascular angioplasty market. Before...

Xenome Names Ian T. Nisbet, PhD as Chief Executive Officer

...me at Millennium he was project leader for the US approval and launch of VELCADE(R) and was part of the team that managed the merger of Millennium and cor Therapeutics in 2001. During his period as CEO of Meditech, Ian led the negotiations with Alchemia that resulted in the first merger of two publicly-t...

The LANCET Published ENDORSE, the Largest Multinational Study Showing That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE Prophylaxis

...th acute medical or surgical patients were eligible for the survey. About cor (Center for Outcomes Research) The Center for Outcomes Research (COR) ser...uments, data management and publication development. Established in 1994, cor is an outgrowth of the Worcester Deep Vein Thrombosis Study, a five-year NI...

More>>